Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: KLH who wrote (2463)	1/15/1999 2:36:00 PM
From: Steven C. Vartan	Respond to of 2553

Credit Suisse First Boston has a buy with a $14 target price. They comment in a 10-26 report that management has kept operating expenses at year ago levels. PaineWebber has as a buy with a $8 target using a 35% discount from 2002 earnings of $0.82 with a 35 multiplier. PW also notes in a Jan report that the expenses for Diacrin are being reworkeds somehow but no details. It must be embarassing for someone other than us investors that mom and dad are up (genz) 79% while the kids are off 67% for tissue and 42% for transgenics. I must be a cynic but perhaps if management (which overlaps) bonuses were based on the kids and not General then we might be doing better.